

PRESS RELEASE

FULCRUM PHARMA PLC

(“the Company”)

Appointment of New COO for US Operations

Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services company, announces that it has appointed John Larus as its new Chief Operating Officer of US Operations as from 12th May 2008.

Mr. Larus brings a broad drug development background to Fulcrum. Most recently, Mr. Larus was Vice President of Clinical Operations North America at AAIPharma, Inc. Mr. Larus was also the President and COO of Maaguzi, LLC, an electronic patient reported outcomes vendor. Prior to Maaguzi, Mr Larus co-founded PharmaLink and then held positions of progressive responsibility at PharmaLinkFHI where his final position was Executive Vice President of Service Operations and CTO. Prior to PharmaLink Mr Larus worked at Novatech Sciences, Clintrial Research, and the SAS Institute.

“I am pleased to have John lead our US operations and join Fulcrum’s management team” says Dr. Frank Armstrong, CEO of Fulcrum. “John’s background and successful client service track record makes him an excellent choice to run our US Operations. He will be an important asset for us as we work to optimize our operations and expand our US business operations”.

Mr. Larus added, “I am excited about working with the talented professionals at Fulcrum, a company with a reputation for providing expert drug development solutions to its customers. As the industry continues to seek ways to develop products more efficiently Fulcrum is positioned to become the market leader drug development consulting.”

About Fulcrum Pharma plc

Fulcrum Pharma plc is a drug development and regulatory services business that provides global expertise to achieve drug development and regulatory approval milestones. Fulcrum Pharma offers immediate access to a highly credible, integrated development team that provides strategic and operational leadership required to ensure that new drugs move smoothly from discovery research to product approval. Fulcrum Pharma operates offices in the US, EU and Japan.

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having successfully floated in March 2000.

For further information, please contact:

Fulcrum Pharma PLC

Geoffrey Smith, Finance Director

Tel: 01442 283600

David Kelly, Global Communications Executive

Tel: 0118 989 5680

Lisa James, Business Development Associate

Tel: 919 228 4458